- $525.08m
- $228.05m
- $0.04m
Obesity stocks slump on Novo's underwhelming 2026 sales forecast
US-listed Novo shares slip after company flags sharp 2026 sales drop
U.S. STOCKS ON THE MOVE-Synchrony Financial, Coinbase, Versant Media Group
U.S. STOCKS ON THE MOVE-Qualcomm, Costco, Topgolf Callaway Brands
Brief: Altimmune Receives FDA Breakthrough Therapy Designation For Pemvidutide In Mash
U.S. STOCKS ON THE MOVE-Alphabet, Liberty Energy, Fortive
Altimmune jumps after US FDA's 'breakthrough' tag for liver disease drug
Structure Therapeutics doubles while other obesity drug developers decline
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
U.S. STOCKS ON THE MOVE-Centrus Energy, Generac Holdings
U.S. STOCKS ON THE MOVE-Centrus Energy, Oracle, Lamb Weston Holdings
U.S. STOCKS ON THE MOVE-Intuitive Machines, Palo Alto Networks, Redwire
Altimmune rises after GLP-1 drug shows benefits in liver disease study
Altimmune's liver disease drug shows benefits in mid-stage study (updated)
Altimmune's drug for a type of liver disease shows benefits in mid-stage study
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
U.S. STOCKS ON THE MOVE-Walt Disney, BankUnited, copper miners
U.S. STOCKS ON THE MOVE-Ideaya Biosciences, Omnicom Group, Targa Resources